(1-三苯甲游基-1H-咪唑-4-基)乙酸 | 168632-03-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: (1-三苯甲游基-1H-咪唑-4-基)乙酸
• 中文别名: 1-三苯甲游基-1H-咪唑-4-基)乙酸
• 英文名称: 1-triphenylmethyl-4-imidazolyl-acetic acid
• 英文别名: 2-[1-(triphenylmethyl)-1H-imidazol-4-yl]acetic acid；[1-(triphenylmethyl)-1H-imidazol-4-yl]acetic acid；1-(triphenylmethyl)-1H-imidazole-4-acetic acid；N-triphenylmethyl-4-imidazole acetic acid；2-(1-trityl-1H-imidazol-4-yl)acetic acid；(1-trityl-1H-imidazol-4-yl)acetic acid；2-(1-tritylimidazol-4-yl)acetic acid
• CAS: 168632-03-9
• 化学式: C₂₄H₂₀N₂O₂
• 分子量: 368.435
• InChiKey: QJSMFMHNXGZJOU-UHFFFAOYSA-N

物化性质

• 沸点：
  553.7±45.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P501,P270,P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313,P301+P312+P330
• 危险性描述：
  H302,H315,H319

反应信息

• 作为反应物：
  描述：

  (1-三苯甲游基-1H-咪唑-4-基)乙酸 在 咪唑 、 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 2.5h， 生成
  参考文献：
  名称：

  Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors

  摘要：

  Aldosterone is a key signaling component of the renin-angiotensin-aldosterone system and as such has been shown to contribute to cardiovascular pathology such as hypertension and heart failure. Aldosterone synthase (CYP11B2) is responsible for the final three steps of aldosterone synthesis and thus is a viable therapeutic target A series of imidazole derived inhibitors, including clinical candidate 7n, have been identified through design and structure-activity relationship studies both in vitro and in vivo. Compound 7n was also found to be a potent inhibitor of 11 beta-hydroxylase (CYP11B1), which is responsible for cortisol production. Inhibition of CYP11B1 is being evaluated in the clinic for potential treatment of hypercortisol diseases such as Cushing's syndrome.

  DOI：

  10.1021/ml400324c
• 作为产物：
  描述：

  甲基(1-trityl-1H-imidazol-4-yl)乙酸酯 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 (1-三苯甲游基-1H-咪唑-4-基)乙酸
  参考文献：
  名称：

  3-Aminopyrrolidinone Farnesyltransferase Inhibitors:  Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell Potency

  摘要：

  A series of macrocyclic 3-aminopyrrolidinone farnesyltransferase inhibitors (FTIs) has been synthesized. Compared with previously described linear 3-aminopyrrolidinone FTIs such as compound 1, macrocycles such as 49 combined improved pharmacokinetic properties with a reduced potential for side effects. In dogs, oral bioavailability was good to excellent, and increases in plasma half-life were due to attenuated clearance. It was observed that in vivo clearance correlated with the flexibility of the molecules and this concept proved useful in the design of FTIs that exhibited low clearance, such as FTI 78. X-ray crystal structures of compounds 49 and 66 complexed with farnesyltransferase (FTase)-farnesyl diphosphate (FPP) were determined, and they provide details of the key interactions in such ternary complexes. Optimization of this 3-aminopyrrolidinone series of compounds led to significant increases in potency, providing 83 and 85, the most potent inhibitors of FTase in cells described to date.

  DOI：

  10.1021/jm010531d

文献信息

• [EN] FUNCTIONALIZABLE MOLECULAR PROBE FOR X-RAY FLUORESCENCE IMAGING AND MULTIMODAL IMAGING<br/>[FR] SONDE MOLÉCULAIRE POUVANT ÊTRE FONCTIONNALISÉE POUR IMAGERIE DE FLUORESCENCE À RAYONS X ET IMAGERIE MULTIMODALE
  申请人：PARIS SCIENCES ET LETTRES - QUARTIER LATIN

  公开号：WO2017005822A1

  公开（公告）日：2017-01-12

  The present invention relates to a X-ray fluorescence molecular probe of formula I or a salt thereof, wherein X, Het 1, R1, Y1, Y2, L and R2 are as defined in the claims. The invention also relates to the use of the probes of the invention for X-ray fluorescence imaging, including in the context of multimodal imaging. The probes of the invention are useful in biological applications of X-ray fluorescence imaging, especially for imaging intracellular organelles and to label biomolecules. The probes of the invention may be functionalized or functionalizable.

  本发明涉及式I的X射线荧光分子探针或其盐，其中X、Het 1、R1、Y1、Y2、L和R2如权利要求中定义。本发明还涉及将本发明的探针用于X射线荧光成像，包括在多模式成像背景下的应用。本发明的探针在X射线荧光成像的生物应用中非常有用，特别适合于成像细胞器内和标记生物分子。本发明的探针可以进行功能化或可功能化处理。
• Antiretroviral hydrazine derivatives
  申请人：Novartis Corporation

  公开号：US05753652A1

  公开（公告）日：1998-05-19

  The invention relates to compounds of formula ##STR1## and salts, pharmaceutical compositions, intermediates and processes of preparation thereof.

  本发明涉及具有公式##STR1##的化合物及其盐、药物组合物、中间体及其制备方法。
• Discovery and Structure−Activity Relationships of Imidazole-Containing Tetrahydrobenzodiazepine Inhibitors of Farnesyltransferase
  作者：Charles Z. Ding、Roberta Batorsky、Rajeev Bhide、Hannguang J. Chao、Young Cho、Saeho Chong、Johnni Gullo-Brown、Peng Guo、Soong Hoon Kim、Frank Lee、Katerina Leftheris、Arthur Miller、Toomas Mitt、Manorama Patel、Becky A. Penhallow、Carol Ricca、William C. Rose、Robert Schmidt、William A. Slusarchyk、Gregory Vite、Ning Yan、Veeraswamy Manne、John T. Hunt

  DOI：10.1021/jm990391w

  日期：1999.12.1

  4,5-Tetrahydro-1-(imidazol-4-ylalkyl)-1,4-benzodiazepines were found to be potent inhibitors of farnesyltransferase (FT). A hydrophobic substituent at the 4-position of the benzodiazepine, linked via a hydrogen bond acceptor, was important to enzyme inhibitory activity. An aryl ring at position 7 or a hydrophobic group linked to the 8-position through an amide, carbamate, or urea linkage was also important

  发现2,3,4,5-四氢-1-（咪唑-4-基烷基）-1,4-苯并二氮杂卓是法呢基转移酶（FT）的有效抑制剂。通过氢键受体连接的苯二氮杂卓的4位疏水取代基对酶抑制活性很重要。7位的芳基环或通过酰胺，氨基甲酸酯或脲键与8位连接的疏水基团对于有效抑制也很重要。2,3,4,5-四氢-1-（1H-咪唑-4-基甲基）-7-（4-吡啶基）-4- [2-（三氟罗甲氧基）苯甲酰基] -1H-1,4-苯并二氮杂（36）的FT IC（50）值为24 nM，在1.25 microM时产生Ras转化的NIH 3T3细胞85％的表型回复，并且EC（50）为160 nM，用于抑制软琼脂中锚定非依赖性生长H-Ras转化的Rat-1细胞的数量。
• Organic compounds
  申请人：Ksander Michael Gary

  公开号：US20070049616A1

  公开（公告）日：2007-03-01

  The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种I式化合物：所述化合物是醛固酮合成酶和芳香化酶的抑制剂，因此可用于治疗由醛固酮合成酶或芳香化酶介导的疾病或疾病。因此，I式化合物可用于治疗低钾血症、高血压、充血性心力衰竭、心房颤动、肾功能衰竭，特别是慢性肾功能衰竭、再狭窄、动脉粥样硬化、X综合征、肥胖、肾病、心肌梗死后、冠心病、炎症、胶原蛋白增生、纤维化如心脏或心肌纤维化以及高血压和内皮功能障碍后的重塑，男性乳房发育过大、骨质疏松症、前列腺癌、子宫内膜异位症、子宫肌瘤、功能性子宫出血、子宫内膜增生、多囊卵巢综合征、不孕症、纤维囊性乳腺疾病、乳腺癌和纤维囊性乳房病。最后，本发明还提供了一种药物组合物。
• CYCLOPROPANECARBOXYLIC ACID DERIVATIVE
  申请人：Nagata Tsutomu

  公开号：US20130012532A1

  公开（公告）日：2013-01-10

  A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R 1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R 2 , R 3 , and R 8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R 4 , R 5 , R 6 , R 7 , R 9 , and R 10 each independently represent a hydrogen atom or the like; and R 11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

  以下是由下列通式（I）表示的化合物或其药学上可接受的盐，其中R1代表C1至C6烷基，该烷基可以被选自取代基A的一个至三个基团取代（取代基A：羟基、卤素基、氰基、硝基、氨基、羧基、C1至C3烷基等）；R2、R3和R8各自独立地代表氢原子或C1至C3烷基；R4、R5、R6、R7、R9和R10各自独立地代表氢原子或类似物；而R11代表氢原子或类似物。该化合物具有TAFIa酶抑制活性，可用作治疗心肌梗塞、心绞痛、急性冠状动脉综合征、脑梗死、深静脉血栓、肺栓塞等疾病的治疗药物。